AWAndreas Wannhoff

Andreas Wannhoff

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andreas Wannhoff has a total of 192 co-authors. Here are the top co-authors by number of shared publications:

  • Karel Caca

    Department of Internal Medicine and Gastroenterology, RKH Hospital Ludwigsburg, Ludwigsburg, Germany

    12 shared publications
  • Wolfgang Stremmel

    Medical Center Baden-Baden, D-76530 Baden-Baden, Germany

    5 shared publications
  • Christian Rupp

    Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany

    4 shared publications
  • Karl Heinz Weiss

    Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany

    4 shared publications
  • Kilian Friedrich

    Department of Internal Medicine IV, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany

    4 shared publications
  • Daniel N. Gotthardt

    Department of Internal Medicine IV, University Hospital Heidelberg, Heidelberg, Germany

    3 shared publications

Latest Publications

  • Endoscopic resection after neoadjuvant therapy for advanced rectal cancer with near-complete response: a retrospective multicentre case series

    by Jakub Krzyzkowiak, George Tribonias, Petros Zormpas, Mathieu Pioche, David Tate, Andrea Sorge, Pedro Barreiro, Shaimaa Elkholy, Mohamed El-Sherbiny, Amol Bapaye, et al.

  • Curriculum on management of acute upper gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement

    by Andrei M. Voiosu, Marine Camus, Mostafa Ibrahim, Tibor Gyökeres, Ricardo Cardoso, Takehide Fukuchi, Krzysztof Kurek, Vikash Lala, Stig Borbjerg Laursen, Alberto Murino, et al.

    1 Before commencing hands-on upper gastrointestinal bleeding (UGIB) training, trainees should have thorough knowledge of: pathology, vascular anatomy, technical use of devices, clinical care pathways, and all relevant components of pre-, intra-, and postprocedural patient care. 2 Preadoption technical skills required for training in the management of UGIB include adequate scope handling, intubation technique, washing and suctioning of residue, mucosal examination, and handling of accessories. 3 Preadoption technical skills required for training in the management of UGIB should be assessed individually based on a competency framework and not solely on numerical thresholds. 4 The integrative skills required for the management of UGIB do not essentially differ from those needed in other endoscopic procedures and should include adequate situational awareness, collaboration, team leadership, and patient communication in order to ensure short- and long-term goals are achieved. 5 The trainee should reach minimum recommended standards for key performance indicators in upper GI endoscopy before starting training in the management of UGIB. 6 Attendance of at least one half-day training session on a dedicated simulator that provides GI bleeding training at the beginning of training for management of UGIB is advised. 7 Trainees should be supervised directly and carefully during UGIB training for a minimum of 20 procedures with endoscopic stigmata of recent hemorrhage in order to prevent failure of hemostasis and ensure adequate trainee skill acquisition. 8 Trainers should take into account pre-endoscopic and intraprocedural factors predicting outcome, technical complexity, and risk of hemostatic failure when deciding appropriateness and degree of trainee involvement in case management. 9 During their training, trainees should be exposed to all hemostatic modalities, as per ESGE guideline recommendations, and the opportunities for teaching arising from the specifics of each UGIB case. 10 Trainers should use “successful hemostasis,” defined as the absence of any further bleeding (persistent or recurrent bleeding), as the ultimate goal of training in the endoscopic management of UGIB. 11 Patients with recurrent bleeding should be treated by experienced endoscopists or by a trainee under their direct supervision owing to the higher risk of failure of conventional endoscopic treatment. 12 Trainers who are teaching management of UGIB should fulfil the same standards as any trainer of basic endoscopy procedures. 13 Trainees should be exposed to multidisciplinary team discussions and care pathways for failed endoscopic treatment of UGIB. 14 Training centers with limited UGIB case volumes are encouraged to offer short-term immersive training in centers with high volume caseloads of UGIB in order to ensure sufficient exposure for trainees. 15 Competency in managing UGIB is defined as the ability to assess the need for endoscopy, and plan and carry out successful hemostasis. 16 Trainees should manage an indicative number of 30 cases in which successful hemostasis is achieved before evaluation of competence in management of UGIB. 17 UGIB-CAT is advised as a formative assessment tool during training to track acquisition of competence and provide trainee feedback. 18 Trainees should undergo a formal summative assessment of competence in managing UGIB during their training. 19 Endoscopists should continue a period of tracking results and mentored practice with an experienced colleague for at least 6 months after achieving competence in managing UGIB. 20 As trainees move to independent practice, they should have established access to or referral pathways for key supporting specialties involved in the nonendoscopic management of acute UGIB (including emergency medicine, surgery, and interventional radiology).


  • Topical budesonide for stricture prevention following wide-field endoscopic submucosal dissection of superficial esophageal neoplasia

    by Tobias Blasberg, Andreas Wannhoff, Moritz Meiborg, Johannes Richl, Lukas Hiebel, Ardian Mekolli, Ahmad Amanzada, Volker Ellenrieder, Jürgen Hochberger, Karel Caca, et al.

    Introduction: Esophageal stricture (ES) is a frequent and clinically significant adverse event after wide-field endoscopic submucosal dissection (ESD) for superficial esophageal neoplasia. Despite multiple prophylactic strategies, prevention remains challenging, and current steroid-based regimens offer limited efficacy. This study evaluated the efficacy and safety of budesonide orodispersible tablets (BOT) for ES prevention after wide-field ESD. Methods: This retrospective, dual-center study evaluated prospectively collected data from patients with superficial esophageal neoplasia undergoing wide-field ESD (≥50% circumferential extent) between August 2020 and August 2024. All patients received BOT (Jorveza® 1 mg twice daily; Dr. Falk Pharma GmbH, Germany) for 4–8 weeks post-ESD. Patients receiving additional stricture-prevention measures were excluded. The primary endpoint was post-ESD stricture. Secondary endpoints included BOT-related adverse events. Results: Twenty patients (mean age 62.8 ± 10.8 years) underwent ESD with BOT prophylaxis. ES occurred in 35.0% overall – 13.3% after resections involving 50–90% of the esophageal circumference and 100% after circumferential (100%) resections. Patients with strictures had greater circumferential resection extent (85.7% vs. 59.2%; p = 0.036). Four strictures were mild (≤ 7 dilations) and three refractory (≥ 8). BOT was well tolerated; two patients (10.0%) developed asymptomatic esophageal candidiasis, and no systemic steroid-related adverse events occurred. Conclusion: BOT prophylaxis was well tolerated and may reduce strictures after non-circumferential resections; however, its protective effect appears limited in circumferential resections. Combination strategies may be warranted in high-risk patients.

  • Open Access

    Practices and Perspectives on Prophylactic Pancreatic Stent Removal Practice: The PIRATE Survey.

    by Marius Zimmerli, Lisette Krassenburg, Enrique De-Madaria, Egle Dieninyte, Paula Ribeiro Sousa, Sophie Schlosser-Hupf, Andreas Wannhoff, Abdullah Murat Buyruk, Lucía Guilabert, Lumir Kunovsky, et al.

    Background and aim: Prophylactic pancreatic stent placement (PPSP) is recommended in high-risk patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) to prevent post-ERCP pancreatitis (PEP). Only a few societies, including the European Society of Gastrointestinal Endoscopy (ESGE), provide guidance on stent management, recommending assessment of spontaneous passage within 5–10 days and endoscopic removal if retained. However, evidence on real-life adherence to these recommendations remains limited. The primary aim was to assess clinical practices related to PPS removal, methods, timing and adherence to current guidelines. Methods: An online 13-item survey was distributed via professional networks and social media between November 2024 and February 2025 to assess current PPSP and removal practices. Results: 322 valid responses were collected (Europe = 285; non-EU = 32; not disclosed = 5). Centres were stratified by annual ERCP volume (procedures/years): 500 (40.1%). Approximately 40 % of respondents did routinely place a PPS in high-risk situations. PPSP was most often inserted after >2 pancreatic duct cannulations (83.5%) or papillectomy (58.7%). Straight 5 Fr, 5 cm stents predominated (54% and 85.4%, respectively). Removal practices varied: 62.7% performed endoscopic retrieval, 47% within one week and 41.6% within four weeks; 55% had no fixed follow-up schedule. Complications of non-removal were reported by 22.7% of centres—mainly pancreatitis (63%)—yet 96% considered these rare. Overall, 31.7% followed ESGE or internal guidance, while 23.6% reported following no guidance. Conclusions: The PIRATE survey reveals that most centres apply heterogenous follow up removal practices despite presence of guidelines.

  • Open Access

    Correction: Practices and Perspectives on Prophylactic Pancreatic Stent Removal Practice: The PIRATE Survey

    by Marius Zimmerli, Lisette Krassenburg, Elisabetta Goni, Henriette Heinrich, Enrique De-Madaria, Egle Dieninyte, Paula Ribeiro Sousa, Sophie Schlosser-Hupf, Andreas Wannhoff, Abdullah Murat Buyruk, et al.

  • Open Access

    Endoscopic Submucosal Dissection for Early Colorectal Carcinoma with High-risk Criteria: Long-term Follow-up from the German Multicenter Registry

    by Sara Moser, Andreas Probst, Alanna Ebigbo, Ingo Steinbrück, Hans-Peter Allgaier, Jürgen Pohl, Roland Reinehr, Viktor Rempel, Michael Anzinger, Franz Ludwig Dumoulin, et al.

    Background and Study Aim Endoscopic submucosal dissection (ESD) is recommended for selected colorectal lesions, especially those with superficial submucosal invasion, enabling en-bloc resection and accurate histopathologic assessment. However, the management of high-risk lesions following ESD, especially regarding additional surgery versus surveillance, remains debated. This study evaluated outcomes after ESD for pT1 colorectal carcinoma, comparing surgical versus conservative management. Patients/Materials and Methods This retrospective multicenter study included 92 patients with pT1 colorectal carcinoma treated by ESD at 14 German referral centers (January 2017–December 2020). Patients were classified as low-risk (n = 34) or high-risk (n = 58) based on histopathologic criteria. Long-term outcomes were compared between low- and high-risk patients, as well as between high-risk patients undergoing additional surgery versus conservative management. Results The overall three-year disease-free survival was 82.6%, without a significant difference between the low-risk (88.2%) and high-risk groups (79.3%; p = 0.276). Among high-risk patients, 56.9% received additional surgery and 43.1% were managed conservatively. Recurrences occurred exclusively in the high-risk group (5.2%). The R0 resection rate after ESD was higher in patients managed without additional surgery than in those who subsequently underwent surgery (76.0% vs. 45.5%; p = 0.019). Conclusion ESD is effective for curative management of selected early colorectal cancers (pT1), particularly in low-risk cases. In high-risk patients, surgery remains the standard, with no recurrences observed after additional surgery in our cohort. A substantial proportion of high-risk patients did not undergo surgery in clinical practice and showed a recurrence rate of 12% (3/25). These findings support current recommendations while reflecting real-world treatment patterns.

  • Open Access

    Feasibility of repeat non-exposed endoscopic full-thickness resection of recurrent or residual colonic adenoma after previous full-thickness resection

    by Andreas Wannhoff, Khalid Takhgiriev, Remy Hosari, Paul Hubbes, Karel Caca

    Endoscopic full-thickness resection (EFTR) can be used to treat recurrent or residual colorectal adenomas. No data are available on treatment of recurrences after EFTR, especially on feasibility and safety of repeat EFTR (re-EFTR) This single-center retrospective study included patients who underwent device-assisted non-exposed re-EFTR in the colorectum. Technical success, adverse events (AEs), and recurrences were analyzed and compared to patients with primary EFTR. Twenty-seven patients who underwent re-EFTR were included. Median age was 75 years (range: 54–85 years) and nine patients were female (33.3%). The indication for re-EFTR was recurrent adenoma in 24 patients (88.9%) and most lesions were in the right-sided colon (n = 22; 81.5%). Technical success was achieved in 22 patients (81.5%). Reasons for failure were failure to reach the lesion in one case and inability to fully mobilize the lesion into the cap in four cases. Follow-up after 2 to 6 months revealed recurrent lesion in four of 24 cases (16.7%) and four more occurred during further follow-up. Surgery was necessary in two cases. AEs occurred in two cases (7.4%). Comparison with primary EFTR showed a trend toward lower technical success (81.5% vs. 100.0%, P = .051), but no differences in recurrence or AEs. Repeat EFTR for recurrence after a previous EFTR is feasible in most patients and only a few patients require surgical resection. The rate of recurrence might be higher than that after primary EFTR, yet there are no differences in AEs.

  • Outcomes of endoscopic retrograde cholangiopancreatography performed via a lumen-apposing gastroenterostomy stent: a multicenter observational study (with videos)

    by Rishad Khan, Remy Hosari, Mouen A. Khashab, Vinay Chandrasekhara, Andrew C. Storm, Samuel Han, Barham Abu Dayyeh, Romina Roshanshad, Farimah Fayyaz, Karel Caca, et al.


  • International, Multicenter Analysis of Endoscopic Full-Thickness Resection of Duodenal Neuroendocrine Tumors

    by Andreas Wannhoff, Zaheer Nabi, Leon M.G. Moons, Gregory Haber, Phillip S. Ge, Tobias Dertmann, Pierre H. Deprez, Wojciech Korcz, Christopher Bouvette, Julius Mueller, et al.

    INTRODUCTION: Nonexposed endoscopic full-thickness resection (EFTR) using a dedicated full-thickness resection device can be used to perform en bloc resection of subepithelial lesions throughout the gastrointestinal tract. In this article, we aim to evaluate the safety and efficacy of EFTR for the management of duodenal neuroendocrine tumors (dNETs). METHODS: This was an international multicenter retrospective study of device-assisted EFTR for dNET. Study outcomes included rates of technical success, R0 resection, and adverse events (AEs). RESULTS: A total of 171 patients were included across 35 centers. Lesions had a median size of 10 mm and were in the duodenal bulb in 143 cases (83.6%). Technical success was achieved in 164 (95.9%) and R0 resection in 123 cases (71.9%). The R0 resection rate for lesions located in the proximal third of the bulb was 62.0% compared with 83.9% for more distal locations ( P = 0.002). The R0 resection rate was not affected by lesion size or depth of invasion. On multivariable analysis, date of resection (2021 onward) and location distal to the proximal third of the duodenal bulb were independent predictors of R0 resection, but not case volume per participating center. Follow-up information was available for 114 patients (66.7%) and demonstrated 2 recurrences over a median follow-up of 10 months. Severe AEs occurred in 3 patients (1.8%). DISCUSSION: EFTR of dNET showed high technical success and R0 resection rates and very low rate of severe AEs. It could become endoscopic treatment of choice for dNET, at least for lesions not within proximity of the pylorus.